ClinicalTrials.gg
Active, not recruitingNCT05851443Updated Jul 7, 2026

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

A Phase 2 interventional study of povorcitinib and placebo in Moderate to Severe Asthma, sponsored by Incyte Corporation. Active, not recruiting at 82 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
441st of 1,353
247 · median 100
Started
2023
with 54 others
Phase 2
292 of 1,695
22 open now
Primary completion
2026-11
later than 38 of 183 live
Registered
1,529th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 441st largest by enrollment of the 1,353 interventional ones that give a count, is one of 55 that started in 2023, is one of 292 in phase 2, reaches primary completion later than 38 of the 183 other live ones, and was the 1,529th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

03

Conditions studied

  • Moderate to Severe Asthma

Browse trials for

Keywords

  • Asthma
  • Moderate to Severe
  • INCB54707
  • Povorcitinib
  • ICS-LABA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician-diagnosed asthma requiring treatment with medium- to high-dose ICS-LABA for at least 12 months prior to screening.
  • Pre-BD \< 80% predicted according to central over read value at Visit 2.
  • Documented historical post-BD reversibility of FEV1 ≥ 12% and ≥ 200 mL in FEV1.
  • At least 2 documented asthma exacerbations (requiring treatment with systemic CS, hospitalization, or emergency department visit) within 12 months prior to screening but not within the past 4 weeks prior to screening
  • ACQ-6 ≥ 1.5 at screening.

Exclusion criteria

Exclusion Criteria:

  • Maintenance use of asthma controllers other than ICS-LABA.
  • Have undergone bronchial thermoplasty.
  • Current smokers or participants with a smoking history of ≥ 10 pack-years and participants using vaping products, including electronic cigarettes.
  • Women who are pregnant (or who are considering pregnancy) or breastfeeding.
  • Current conditions or history of other diseases, as follows:
  • pulmonary disease other than asthma ,Thrombocytopenia, coagulopathy, or dysfunction.
  • Venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, moderate to severe heart failure ( Class III or IV), cerebrovascular accident, myocardial infarction, coronary stenting, or CABG surgery.
  • Diagnosis of other significant cardiovascular diseases, including but not limited to angina, peripheral arterial disease, or uncontrolled arrhythmias such as atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, and forms of carditis.
  • Recipient of an organ transplant that requires continued .
  • Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich syndrome).
  • Any or history of malignancies.
  • Chronic or recurrent infectious disease.
  • Receipt of any biologic drugs used for asthma \< 12 weeks or 5 half-lives (if known), whichever is longer, prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
247 participants (actual)

Study arms

  • Placebo comparator
    Inhaled Corticoseroid Long Acting Beta-Agonist(ICS-LABA) + placebo

    Participants will receive stable background therapy with ICS-LABA in combination with placebo once daily (QD) for 24 weeks during the placebo-controlled period. Participants will be allocated to 1 of 3 doses of povorcitinib during the extension period of 28 weeks

    Other: placebo · Drug: ICS-LABA

  • Experimental
    ICS-LABA + povorcitinib Dose 1

    Participants will receive stable background therapy with ICS-LABA in combination with povorcitinib dose 1 once daily (QD) for 24 weeks during the placebo-controlled period, and Participants will continue to take the same dose of povorcitinib during the extension period of 28 weeks

    Drug: povorcitinib · Drug: ICS-LABA

  • Experimental
    ICS-LABA + povorcitinib Dose 2

    Participants will receive stable background therapy with ICS-LABA in combination with povorcitinib dose 2 once daily (QD) for 24 weeks during the placebo-controlled period, and Participants will continue to take the same dose of povorcitinib during the extension period of 28 weeks

    Drug: povorcitinib · Drug: ICS-LABA

  • Experimental
    ICS-LABA + povorcitinib Dose 3

    Participants will receive stable background therapy with ICS-LABA in combination with povorcitinib dose 3 once daily (QD) for 24 weeks during the placebo-controlled period, and Participants will continue to take the same dose of povorcitinib during the extension period of 28 weeks

    Drug: povorcitinib · Drug: ICS-LABA

Interventions

  • povorcitinib

    Also known as: INCB54707

  • Otherplacebo

    placebo

  • DrugICS-LABA

    Background Therapy

06

What researchers measure

Primary outcomes

  1. Absolute change in pre-bronchodilator forced expiratory volume in the first 1 second (pre-BD FEV1)

    To assess the effect of povorcitinib on lung function (pre-BD FEV1) between baseline and week 24

    Time frame: Baseline ; Week 24

Secondary outcomes

  1. Number of asthma exacerbations during the Placebo Controlled (PC) period

    Defined as a worsening of asthma

    Time frame: Up to 28 weeks

  2. Absolute change from baseline in pre-BD FEV1 at each visit

    Time frame: Up to 14 months

  3. Percent change from baseline in pre-BD FEV1 at each visit

    Time frame: Up to 14 months

  4. Absolute change from baseline in post-BD FEV1 at week 24

    Time frame: Baseline; Week 24

  5. Percent change from baseline in post-BD FEV1 at week 24

    Time frame: Baseline; Week 24

  6. Absolute change from baseline in pre-BD FVC at each visit

    Time frame: Up to 14 months

  7. Percent change from baseline in pre-BD FVC at each visit

    Time frame: Up to 14 months

07

Study locations

82 sites
  • Allervie Clinical Research
    Birmingham, Alabama 35209, United States
  • Kern Allergy Medical Clinic, Inc
    Bakersfield, California 93301, United States
  • Integrated Research of Inland, Inc
    Upland, California 91786, United States
  • Qway Research
    Hialeah, Florida 33010, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • Care Research Inc
    Miami, Florida 33130, United States
  • Verus Clinical Research Corp
    Miami, Florida 33135, United States
  • Dr. de Armas Research Center, Llc
    Miami, Florida 33174, United States
  • Care Research Center, Inc
    Miami, Florida 33175, United States
  • Anderson Allergy and Asthma
    Orlando, Florida 32806, United States
  • Heuer Md Research Inc
    Orlando, Florida 32819, United States
  • Advanced Clinical Research Atlanta
    Atlanta, Georgia 30309, United States
  • Covenant Pulmonary Critical Care
    East Point, Georgia 30344, United States
  • Northshore Medical Group
    Glenview, Illinois 60026, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Aa Medical Research Center
    Flint, Michigan 48504, United States
  • Revive Research Institute
    Southfield, Michigan 48075, United States
  • Northwell Health Physician Partners
    New Hyde Park, New York 11040, United States
  • Pioneer Clinical Research Ny
    New York, New York 10016, United States
  • Montefiore Medical Center (Mmc)
    The Bronx, New York 10461, United States
  • Onsite Clinical Solutions, Llc Charlotte Central Office
    Charlotte, North Carolina 28277, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Howland Allergy and Asthma Pllc Dba Orion Clinical Research
    Austin, Texas 78759, United States
  • Linq Research, Llc
    Pearland, Texas 77584, United States
  • Quality Assurance Research Center
    San Antonio, Texas 78212, United States
  • Fundacion Respirar
    Buenos Aires, 01426, Argentina
  • Fundacion Cidea
    Buenos Aires, 1125 ABE, Argentina
  • Mautalen Salud E Investigacion
    Buenos Aires, C1128AAF, Argentina
  • Care: Centro de Alergia Y Enfermedades Respiratorias
    CABA, C1414AIF, Argentina
  • INAER
    Capitalfederal, C1425BEN, Argentina
  • Centro de Medicina Respiratoria
    Concepción del Uruguay, 03260, Argentina
  • Instituto de Medicina Respiratoria - Imer
    Córdoba, X5003DCE, Argentina
  • Fundacion Enfisema
    Mar del Plata, B7612ENA, Argentina
  • Centro Medico Dharma
    Mendoza, 05500, Argentina
  • Polo de Salud Vistalba
    Mendoza, 05509, Argentina
  • Fundacion Scherbovsky
    Mendoza, M5500AXR, Argentina
  • INSARES
    Mendoza, MENDOZA (5500), Argentina
  • Centro Respiratorio Quilmes
    Quilmes, 01878, Argentina
  • Centro Respiratorio Infantil
    Rosario, 02000, Argentina
  • Instituto de Diagnostico Abc
    Rosario, 02000, Argentina
  • Instituto Especialidades de La Salud Rosario
    Rosario, 02000, Argentina
  • Instituto Medico de La Fundacion Estudios Clinicos
    Rosario, S2000 DEJ, Argentina
  • Centro Medico Respire
    San Fernando, 01644, Argentina
  • Ierim Instituto de Enfermedades Respiratorias E Investigacion Medica
    San Juan Bautista, 01888, Argentina
  • Ipr Instituto de Patologias Respiratorias
    San Miguel de Tucumán, 04000, Argentina
  • Cimer - Centro Integral de Medicina Respiratoria Srl
    San Miguel de Tucumán, T4000 CBC, Argentina
  • Iba Medica
    Santa Fe, S3000ASF, Argentina
  • Synergy Respiratory Care
    Sherwood Park, Alberta T8H 0N2, Canada
  • Centre For Lung Health
    Vancouver, British Columbia V5Z 1M9, Canada
  • Dynamic Drug Advancement
    Ajax, Ontario L1S2J5, Canada
  • Ottawa Allergy Research Corporation
    Ottawa, Ontario K1H 1E4, Canada
  • S. Fikry Medicine Professional Corporation
    Waterloo, Ontario N2J 1C4, Canada
  • Dr. Syed Anees Medicine Professional Corporation
    Windsor, Ontario N8X 1T3, Canada
  • Pneumologische Gemeinschaftspraxis Kroker-Schaeben-Schmidt
    Bendorf, 56170, Germany
  • Universitatsklinikum Bonn Aoer
    Bonn, 53127, Germany
  • Ikf Pneumologie Frankfurt, Clinical Research Center Respiratory Diseases
    Frankfurt am Main, 60596, Germany
  • Hannover Medical School
    Hanover, 30625, Germany
  • Ikf Pneumologie Mainz
    Mainz, 55128, Germany
  • Nihonbashi Medical and Allergy Clinic
    Chūōku, 103-0022, Japan
  • Fukuwa Clinic
    Chūōku, 104-0031, Japan
  • National Hospital Organization Fukuoka National Hospital
    Fukuoka, 811-1394, Japan
  • Kishiwada City Hospital
    Kishiwada, 596-8501, Japan
  • Kirigaoka Tsuda Hospital
    Kitakyushu-shi, 802-0052, Japan
  • Tohno Chuo Clinic
    Mizunami-shi, 509-6134, Japan
  • Kyosokai Amc Nishi-Umeda Clinic
    Osaka, 530-0001, Japan
  • Lee Clinic
    Osaka, 531-0073, Japan
  • Sakaide City Hospital
    Sakaide-shi, 762-8550, Japan
  • Idaimae Minami Yojo Int Clinic
    Sapporo, 064-0804, Japan
  • Tokyo Shinagawa Hospital
    Shinagawa-ku, 140-8522, Japan
  • Takahashi Medical Clinic
    Tokyo, 185-0014, Japan
  • Kouwa Clinic
    Toshima-ku, 170-0003, Japan
  • Local Independent Administrative Institution Mie Prefectural General Medical Center
    Yokkaichi-shi, 510-8561, Japan
  • Kaiseikai Kita Shin Yokohama Internal Medicine Clinic
    Yokohama, 223-0059, Japan
  • Allergy Clinic Homeo Medicus
    Bialystok, 15-687, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
  • Nzoz Atopia
    Krakow, 31-142, Poland
  • Szpital Specjalistyczny Cdt Medicus
    Lubin, 59-300, Poland
  • Ostrowieckie Centrum Medyczne Spka Cywilna Anna Olech-Cudzik Krzysztof Cudzik
    Ostrowiec Świętokrzyski, 27-400, Poland
  • Pim Mswia
    Warsaw, 02-507, Poland
  • Giromed Institute/ Clinica Tres Torrres
    Barcelona, 08017, Spain
  • Hospital Clinic Barcelona Main
    Barcelona, 08036, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Nov 2026, 40 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 40 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 9, 2023
StartActual
Jul 11, 2023
Primary completionEst.
Nov 20, 2026
CompletionEst.
Jul 5, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05851443
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
May 9, 2023
Start date
Jul 11, 2023
Primary completion
Nov 20, 2026 (estimated)
Completion
Jul 5, 2027 (estimated)
Last update
Jul 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion